HEADER IMMUNE SYSTEM 12-JAN-06 2FO4 TITLE ENHANCED MHC CLASS I BINDING AND IMMUNE RESPONSES THROUGH ANCHOR TITLE 2 MODIFICATION OF THE NON-CANONICAL TUMOR ASSOCIATED MUC1-8 PEPTIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: H-2 CLASS I HISTOCOMPATIBILITY ANTIGEN, K-B ALPHA CHAIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: EXTRACELLULAR DOMAINS, RESIDUES 1-274; COMPND 5 SYNONYM: H-2KB; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: BETA-2-MICROGLOBULIN; COMPND 9 CHAIN: B; COMPND 10 ENGINEERED: YES; COMPND 11 MOL_ID: 3; COMPND 12 MOLECULE: 8-MER FROM MUCIN-1; COMPND 13 CHAIN: P; COMPND 14 SYNONYM: MUCIN 1, TRANSMEMBRANE, MUC-1, POLYMORPHIC EPITHELIAL MUCIN, COMPND 15 PEM, PEMT, EPISIALIN, TUMOR-ASSOCIATED MUCIN, CARCINOMA-ASSOCIATED COMPND 16 MUCIN, TUMOR-ASSOCIATED EPITHELIAL MEMBRANE ANTIGEN, EMA, H23AG, COMPND 17 PEANUT- REACTIVE URINARY MUCIN, PUM, BREAST CARCINOMA-ASSOCIATED COMPND 18 ANTIGEN DF3, CD227 ANTIGEN; COMPND 19 ENGINEERED: YES; COMPND 20 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: MUS MUSCULUS; SOURCE 3 ORGANISM_COMMON: HOUSE MOUSE; SOURCE 4 ORGANISM_TAXID: 10090; SOURCE 5 EXPRESSION_SYSTEM: DROSOPHILA MELANOGASTER; SOURCE 6 EXPRESSION_SYSTEM_COMMON: FRUIT FLY; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7227; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: SC2 CELLS; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PRMHA-3; SOURCE 11 MOL_ID: 2; SOURCE 12 ORGANISM_SCIENTIFIC: MUS MUSCULUS; SOURCE 13 ORGANISM_COMMON: HOUSE MOUSE; SOURCE 14 ORGANISM_TAXID: 10090; SOURCE 15 EXPRESSION_SYSTEM: DROSOPHILA MELANOGASTER; SOURCE 16 EXPRESSION_SYSTEM_COMMON: FRUIT FLY; SOURCE 17 EXPRESSION_SYSTEM_TAXID: 7227; SOURCE 18 EXPRESSION_SYSTEM_STRAIN: SC2 CELLS; SOURCE 19 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 20 EXPRESSION_SYSTEM_PLASMID: PRMHA-3; SOURCE 21 MOL_ID: 3; SOURCE 22 SYNTHETIC: YES; SOURCE 23 OTHER_DETAILS: THE 8-RESIDUE PEPTIDE OF MUCIN 1 WAS CHEMICALLY SOURCE 24 SYNTHESIZED. KEYWDS ANCHOR MODIFICATIONS, H-2KB, MUC1, NON-CANONICAL PEPTIDE, MUC1-8, KEYWDS 2 VACCINE DESIGN, IMMUNE SYSTEM EXPDTA X-RAY DIFFRACTION AUTHOR E.LAZOURA,P.A.RAMSLAND REVDAT 7 25-OCT-23 2FO4 1 REMARK REVDAT 6 10-NOV-21 2FO4 1 SEQADV HETSYN REVDAT 5 29-JUL-20 2FO4 1 COMPND REMARK HETNAM LINK REVDAT 5 2 1 SITE ATOM REVDAT 4 18-OCT-17 2FO4 1 REMARK REVDAT 3 13-JUL-11 2FO4 1 VERSN REVDAT 2 24-FEB-09 2FO4 1 VERSN REVDAT 1 14-NOV-06 2FO4 0 JRNL AUTH E.LAZOURA,J.LODDING,W.FARRUGIA,P.A.RAMSLAND,J.STEVENS, JRNL AUTH 2 I.A.WILSON,G.A.PIETERSZ,V.APOSTOLOPOULOS JRNL TITL ENHANCED MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I BINDING JRNL TITL 2 AND IMMUNE RESPONSES THROUGH ANCHOR MODIFICATION OF THE JRNL TITL 3 NON-CANONICAL TUMOUR-ASSOCIATED MUCIN 1-8 PEPTIDE JRNL REF IMMUNOLOGY V. 119 306 2006 JRNL REFN ISSN 0019-2805 JRNL PMID 17067310 JRNL DOI 10.1111/J.1365-2567.2006.02434.X REMARK 2 REMARK 2 RESOLUTION. 2.70 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.70 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 41.80 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 94.3 REMARK 3 NUMBER OF REFLECTIONS : 14860 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.193 REMARK 3 FREE R VALUE : 0.248 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 1449 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.70 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.87 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 78.10 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2850 REMARK 3 BIN FREE R VALUE : 0.3470 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : 181 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.026 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3117 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 80 REMARK 3 SOLVENT ATOMS : 103 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 54.40 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 37.50 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.28 REMARK 3 ESD FROM SIGMAA (A) : 0.34 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.38 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.44 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.006 REMARK 3 BOND ANGLES (DEGREES) : 1.400 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 24.70 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.790 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : ISOTROPIC REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2FO4 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 16-JAN-06. REMARK 100 THE DEPOSITION ID IS D_1000036107. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 17-FEB-05 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.6 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV REMARK 200 INTENSITY-INTEGRATION SOFTWARE : R-AXIS REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 14860 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.700 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 97.9 REMARK 200 DATA REDUNDANCY : 6.400 REMARK 200 R MERGE (I) : 0.10400 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 17.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.70 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.80 REMARK 200 COMPLETENESS FOR SHELL (%) : 96.2 REMARK 200 DATA REDUNDANCY IN SHELL : 5.30 REMARK 200 R MERGE FOR SHELL (I) : 0.43400 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.300 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: PDB ENTRY 1G7Q REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 59.42 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.03 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 1.9M SODIUM/POTASIUM PHOSPHATE, 2% REMARK 280 MPD, PH 6.6, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X+1/2,Y+1/2,-Z REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 67.63000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 43.94500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 67.63000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 43.94500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 6690 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 18550 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -75.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, P, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 29 -129.70 67.53 REMARK 500 SER A 38 -7.87 -56.78 REMARK 500 TYR A 123 -70.71 -116.66 REMARK 500 GLU A 196 65.13 80.34 REMARK 500 ASP A 197 49.99 28.51 REMARK 500 PRO A 210 -179.28 -65.38 REMARK 500 ILE A 225 -54.30 -29.39 REMARK 500 ARG A 273 -169.00 -113.39 REMARK 500 PRO B 47 -101.43 -52.76 REMARK 500 LYS B 48 85.81 -63.31 REMARK 500 PRO P 7 144.16 -38.32 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1G7Q RELATED DB: PDB REMARK 900 THE SAME PROTEIN COMPLEXED WITH MUC1-8 PEPTIDE DBREF 2FO4 A 1 274 UNP P01901 HA1B_MOUSE 22 295 DBREF 2FO4 B 1 99 UNP P01887 B2MG_MOUSE 21 119 DBREF 2FO4 P 1 8 UNP Q16615 MUC1_HUMAN 920 927 SEQADV 2FO4 PHE P 5 UNP Q16615 THR 924 ENGINEERED MUTATION SEQADV 2FO4 LEU P 8 UNP Q16615 ALA 927 ENGINEERED MUTATION SEQRES 1 A 274 GLY PRO HIS SER LEU ARG TYR PHE VAL THR ALA VAL SER SEQRES 2 A 274 ARG PRO GLY LEU GLY GLU PRO ARG TYR MET GLU VAL GLY SEQRES 3 A 274 TYR VAL ASP ASP THR GLU PHE VAL ARG PHE ASP SER ASP SEQRES 4 A 274 ALA GLU ASN PRO ARG TYR GLU PRO ARG ALA ARG TRP MET SEQRES 5 A 274 GLU GLN GLU GLY PRO GLU TYR TRP GLU ARG GLU THR GLN SEQRES 6 A 274 LYS ALA LYS GLY ASN GLU GLN SER PHE ARG VAL ASP LEU SEQRES 7 A 274 ARG THR LEU LEU GLY TYR TYR ASN GLN SER LYS GLY GLY SEQRES 8 A 274 SER HIS THR ILE GLN VAL ILE SER GLY CYS GLU VAL GLY SEQRES 9 A 274 SER ASP GLY ARG LEU LEU ARG GLY TYR GLN GLN TYR ALA SEQRES 10 A 274 TYR ASP GLY CYS ASP TYR ILE ALA LEU ASN GLU ASP LEU SEQRES 11 A 274 LYS THR TRP THR ALA ALA ASP MET ALA ALA LEU ILE THR SEQRES 12 A 274 LYS HIS LYS TRP GLU GLN ALA GLY GLU ALA GLU ARG LEU SEQRES 13 A 274 ARG ALA TYR LEU GLU GLY THR CYS VAL GLU TRP LEU ARG SEQRES 14 A 274 ARG TYR LEU LYS ASN GLY ASN ALA THR LEU LEU ARG THR SEQRES 15 A 274 ASP SER PRO LYS ALA HIS VAL THR HIS HIS SER ARG PRO SEQRES 16 A 274 GLU ASP LYS VAL THR LEU ARG CYS TRP ALA LEU GLY PHE SEQRES 17 A 274 TYR PRO ALA ASP ILE THR LEU THR TRP GLN LEU ASN GLY SEQRES 18 A 274 GLU GLU LEU ILE GLN ASP MET GLU LEU VAL GLU THR ARG SEQRES 19 A 274 PRO ALA GLY ASP GLY THR PHE GLN LYS TRP ALA SER VAL SEQRES 20 A 274 VAL VAL PRO LEU GLY LYS GLU GLN TYR TYR THR CYS HIS SEQRES 21 A 274 VAL TYR HIS GLN GLY LEU PRO GLU PRO LEU THR LEU ARG SEQRES 22 A 274 TRP SEQRES 1 B 99 ILE GLN LYS THR PRO GLN ILE GLN VAL TYR SER ARG HIS SEQRES 2 B 99 PRO PRO GLU ASN GLY LYS PRO ASN ILE LEU ASN CYS TYR SEQRES 3 B 99 VAL THR GLN PHE HIS PRO PRO HIS ILE GLU ILE GLN MET SEQRES 4 B 99 LEU LYS ASN GLY LYS LYS ILE PRO LYS VAL GLU MET SER SEQRES 5 B 99 ASP MET SER PHE SER LYS ASP TRP SER PHE TYR ILE LEU SEQRES 6 B 99 ALA HIS THR GLU PHE THR PRO THR GLU THR ASP THR TYR SEQRES 7 B 99 ALA CYS ARG VAL LYS HIS ASP SER MET ALA GLU PRO LYS SEQRES 8 B 99 THR VAL TYR TRP ASP ARG ASP MET SEQRES 1 P 8 SER ALA PRO ASP PHE ARG PRO LEU MODRES 2FO4 ASN A 86 ASN GLYCOSYLATION SITE MODRES 2FO4 ASN A 176 ASN GLYCOSYLATION SITE HET NAG C 1 14 HET FUC C 2 10 HET NAG A 900 14 HET PO4 A2001 5 HET PO4 A2002 5 HET MPD A1002 8 HET MPD A1004 8 HET MPD B1001 8 HET MPD B1003 8 HETNAM NAG 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE HETNAM FUC ALPHA-L-FUCOPYRANOSE HETNAM PO4 PHOSPHATE ION HETNAM MPD (4S)-2-METHYL-2,4-PENTANEDIOL HETSYN NAG N-ACETYL-BETA-D-GLUCOSAMINE; 2-ACETAMIDO-2-DEOXY-BETA- HETSYN 2 NAG D-GLUCOSE; 2-ACETAMIDO-2-DEOXY-D-GLUCOSE; 2-ACETAMIDO- HETSYN 3 NAG 2-DEOXY-GLUCOSE; N-ACETYL-D-GLUCOSAMINE HETSYN FUC ALPHA-L-FUCOSE; 6-DEOXY-ALPHA-L-GALACTOPYRANOSE; L- HETSYN 2 FUC FUCOSE; FUCOSE FORMUL 4 NAG 2(C8 H15 N O6) FORMUL 4 FUC C6 H12 O5 FORMUL 6 PO4 2(O4 P 3-) FORMUL 8 MPD 4(C6 H14 O2) FORMUL 12 HOH *103(H2 O) HELIX 1 1 ALA A 49 GLU A 55 5 7 HELIX 2 2 GLY A 56 TYR A 85 1 30 HELIX 3 3 ASP A 137 ALA A 150 1 14 HELIX 4 4 GLY A 151 GLY A 162 1 12 HELIX 5 5 GLY A 162 GLY A 175 1 14 HELIX 6 6 GLY A 175 LEU A 180 1 6 HELIX 7 7 ILE A 225 MET A 228 5 4 HELIX 8 8 LYS A 253 TYR A 257 5 5 SHEET 1 A 8 GLU A 46 PRO A 47 0 SHEET 2 A 8 THR A 31 ASP A 37 -1 N ARG A 35 O GLU A 46 SHEET 3 A 8 ARG A 21 VAL A 28 -1 N VAL A 28 O THR A 31 SHEET 4 A 8 HIS A 3 VAL A 12 -1 N PHE A 8 O VAL A 25 SHEET 5 A 8 THR A 94 VAL A 103 -1 O CYS A 101 N LEU A 5 SHEET 6 A 8 LEU A 109 TYR A 118 -1 O LEU A 110 N GLU A 102 SHEET 7 A 8 CYS A 121 LEU A 126 -1 O ILE A 124 N TYR A 116 SHEET 8 A 8 TRP A 133 ALA A 135 -1 O THR A 134 N ALA A 125 SHEET 1 B 4 LYS A 186 ARG A 194 0 SHEET 2 B 4 LYS A 198 PHE A 208 -1 O TRP A 204 N HIS A 188 SHEET 3 B 4 PHE A 241 PRO A 250 -1 O ALA A 245 N CYS A 203 SHEET 4 B 4 GLU A 229 LEU A 230 -1 N GLU A 229 O SER A 246 SHEET 1 C 4 LYS A 186 ARG A 194 0 SHEET 2 C 4 LYS A 198 PHE A 208 -1 O TRP A 204 N HIS A 188 SHEET 3 C 4 PHE A 241 PRO A 250 -1 O ALA A 245 N CYS A 203 SHEET 4 C 4 ARG A 234 PRO A 235 -1 N ARG A 234 O GLN A 242 SHEET 1 D 4 GLU A 222 GLU A 223 0 SHEET 2 D 4 ILE A 213 LEU A 219 -1 N LEU A 219 O GLU A 222 SHEET 3 D 4 THR A 258 HIS A 263 -1 O HIS A 260 N THR A 216 SHEET 4 D 4 LEU A 270 LEU A 272 -1 O LEU A 272 N CYS A 259 SHEET 1 E 4 GLN B 6 SER B 11 0 SHEET 2 E 4 ASN B 21 PHE B 30 -1 O ASN B 24 N TYR B 10 SHEET 3 E 4 PHE B 62 PHE B 70 -1 O PHE B 62 N PHE B 30 SHEET 4 E 4 GLU B 50 PHE B 56 -1 N SER B 55 O TYR B 63 SHEET 1 F 4 LYS B 44 LYS B 45 0 SHEET 2 F 4 ILE B 35 LYS B 41 -1 N LYS B 41 O LYS B 44 SHEET 3 F 4 TYR B 78 HIS B 84 -1 O ALA B 79 N LEU B 40 SHEET 4 F 4 LYS B 91 TYR B 94 -1 O LYS B 91 N VAL B 82 SSBOND 1 CYS A 101 CYS A 164 1555 1555 2.04 SSBOND 2 CYS A 203 CYS A 259 1555 1555 2.02 SSBOND 3 CYS B 25 CYS B 80 1555 1555 2.03 LINK ND2 ASN A 86 C1 NAG A 900 1555 1555 1.45 LINK ND2 ASN A 176 C1 NAG C 1 1555 1555 1.45 LINK O6 NAG C 1 C1 FUC C 2 1555 1555 1.40 CISPEP 1 TYR A 209 PRO A 210 0 0.16 CISPEP 2 HIS B 31 PRO B 32 0 0.05 CRYST1 135.260 87.890 45.160 90.00 90.00 90.00 P 21 21 2 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.007393 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011378 0.000000 0.00000 SCALE3 0.000000 0.000000 0.022143 0.00000